rdrp-in-2

RdRP-IN-2 is a RNA dependent RNA polymerase (RdRp) inhibitor. It significantly inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 µM.It also inhibits Feline coronavirus (FIPV) replication.

SARS-CoV-2-IN-67 (Compound 16), a derivative of vitamin K, exhibits anti-SARS-CoV-2 properties, with an effective concentration (EC50) of 64.8 μM in VeroE6/TMPRSS2 cells, and inhibits SARS-CoV-2 RdRp activity [1].

NITD-2 is a dengue virus (DENV) polymerase inhibitor, inhibits the DENV RdRp-mediated RNA elongation. NITD-2 penetrates cell membrane poorly. Dengue virus (DENV) is the most prevalent mosquito- borne viral pathogen in humans. Neither vaccine nor antiviral therapy is currently available for DENV.

RdRP-IN-7, a RNA-dependent RNA polymerase (RdRp) inhibitor, demonstrates efficacy against SARS-CoV-2 infection with an inhibitory concentration (IC50) of 8.2 μM and (IC90) of 14.1 μM, alongside a cytotoxic concentration (CC90) of 79.1 μM, rendering it suitable for antiviral research [1].

HeE1-2Tyr, a pyridobenzothiazole compound, is a flavivirus RNA dependent RNA polymerases (RdRp) inhibitor. It significantly inhibits West Nile, Dengue and SARS-CoV-2 RdRps (IC50 of 27.6 µM) activity in vitro.

AVG-233 is an orally available RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that blocks respiratory syncytial virus and SARS-CoV-2 replication.AVG-233 is used in the study of respiratory syncytial virus infections.